Effect of Antioxidant Cocktail in Beta-thalassemia/Hb E Patients

Status Completed

Clinical Trial Summary

The purpose of this study is to determine the efficacy of antioxidant cocktails on the alleviation of oxidative stress and iron overload in beta-thalassemia/Hb E patients.

Clinical Trial Description

60 cases of beta-thalassemia/Hb E patients. All patients will be diagnosed with hemoglobin typing of beta-thalassemia/Hb E disease and not receive blood transfusion or any treatment at least 3 months prior study. The study will be randomized controlled trial that designed before and after treatment with antioxidant cocktail. The antioxidant cocktail consists of vitamin E 400 IU/day, curcuminoids 500 mg/day, N-acetylcysteine 200 mg/day and deferiprone 50 mg/kg/day. All patients will receive antioxidant cocktail daily for 12 months. The patients will be regularly followed up and analyzed biochemical parameters every two months during treatment and after withdrawal for 3 months. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01597765
Study type	Interventional
Source	Mahidol University
Contact
Status	Completed
Phase	N/A
Start date	June 2009
Completion date	June 2011

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04398628` - ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
Completed	`NCT04614779` - Long-term Clinical Study of CN128 in Thalassemia Patients	Phase 2
Completed	`NCT01158794` - Genes Influencing Iron Overload State
Recruiting	`NCT02995707` - The Effective and Safety of Thalidomide in NTDT	Phase 2
Active, not recruiting	`NCT01935661` - A Case Control Study to Evaluate the Cognitive and Brain Function of β-thalassemia Patients.
Terminated	`NCT01319851` - Alefacept and Allogeneic Hematopoietic Stem Cell Transplantation	N/A
Completed	`NCT00901199` - Combined Chelation Therapy in Patients With Transfusion Dependent Thalassemia and Iron Overload	Phase 2
Terminated	`NCT00034528` - Stem Cell Transplantation After Reduced-Dose Chemotherapy for Patients With Sickle Cell Disease or Thalassemia	Phase 2
Active, not recruiting	`NCT03655678` - A Safety and Efficacy Study Evaluating CTX001 in Subjects With Transfusion-Dependent β-Thalassemia	Phase 2/Phase 3
Recruiting	`NCT05508932` - Atrial Fibrillation in Beta-Thalassemia
Completed	`NCT03609827` - Study of Melphalan Drug Exposure in Pediatric Hematopoietic Stem Cell Transplant Patients
Completed	`NCT03117192` - Zinc Supplementation on Cellular Immunity in Thalassemia Major	Phase 4
Completed	`NCT03095326` - Pneumococcal Vaccination for Splenectomised Thalassemia Major Patients in Indonesia	Phase 4
Completed	`NCT01443312` - Demographic, Clinical, Laboratory and Genetical Characteristics of Patients With Beta Thalassemia Intermedia
Completed	`NCT00744692` - Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders	Phase 1
Completed	`NCT00235391` - Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload	Phase 3
Not yet recruiting	`NCT06058260` - Assessment of Cognitive Function and Quality of Life in Thalassemic Children at Sohag University Hospital
Completed	`NCT05529550` - Assessment of Nutritional Status and Role of Insulin-like Growth Factor-1 in Children
Completed	`NCT04582110` - The Role of OCTA in Patients Affected by Beta Thalassemia
Recruiting	`NCT06213402` - RADeep Multicenter European Epidemiological Platform for Patients Diagnosed With Rare Anemia Disorders (RADs)